Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Treating PNH: Understanding Complement Inhibitors, Modes of Administration, and Coordinated Patient Care Needs : Episode 16
Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway
The panelists provide their final thoughts, highlighting financial considerations in PNH treatment.
EP: 1.PNH Overview and Pathophysiology
EP: 2.Intravascular and Extravascular Hemolysis MoA in PNH
EP: 3.Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming
EP: 4.Key Treatment Considerations for Patients Diagnosed With PNH
EP: 5.Complement System Role in PNH Treatment Approach
EP: 6.Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management
EP: 7.Efficacy End Points For PNH Treatment
EP: 8.Efficacy and Safety Trials Results of Complement Inhibitors
EP: 9.Treatment Adherence and Cost Considerations Surrounding Various Routes of PNH Treatment Administration
EP: 10.Investigational Therapies Paving New PNH Treatment Pathways
EP: 11.Key Financial Factors Associated With Typical PNH Treatment Journey
EP: 12.Navigating Transfusion Requirements in PNH Treatment
EP: 13.Considerations for Managing PNH Treatment Complications
EP: 14.Infection Risk Management Counseling For Patients Receiving Treatment for PNH
EP: 15.Ensuring PNH Treatment Access and Adherence to Therapies
Now Viewing
EP: 16.Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway
Video content above is prompted by the following question:
- How do financial considerations influence your treatment decision-making process?
Related Videos
Related Content
ALL Disparities, Treatment Gaps: AYA Patients Face Unique Challenges
June 4th 2025Article
Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and unmet needs for effective third-line treatments, highlighting urgent care gaps.
Read More
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study
May 17th 2025Article
The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).
Read More
